Navigation Links
NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
Date:6/3/2013

AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway. Indoximod was tested in a Phase 1 study in combination with docetaxel and in a Phase 1B/2 study in combination with dendritic cell cancer vaccine (AD.p53DC).  In both studies, data indicated that indoximod was well tolerated when combined with these anti-cancer agents. The data also indicated promising signs of anti-tumor activity. Based on these results, NewLink has recently advanced indoximod into two separate Phase 2 cancer trials in patients with metastatic breast cancer.

The Phase 1 trial of indoximod in combination with docetaxel was conducted in patients that failed prior treatments to determine the maximum tolerated dose and evaluate the safety and activity for the combination of indoximod and docetaxel. The data showed that in 22 evaluable patients, 18 percent (4/22) exhibited a partial response and 41 percent (9/22) had stable disease. Data indicated that the combination therapy was well tolerated with no increase in expected toxicities or unexpected drug-drug interactions. Further, the pharmacokinetic profile of the combination therapy was similar to the profile of each drug as a single agent. Based on these results, a randomized Phase 2 clinical study was initiated evaluating the potential of indoximod in combination with docetaxel in patients with metastatic breast cancer using 1200 mg twice per day (BID) of indoximod and 75 mg/m2 of docetaxel once every three weeks.

The Phase 1B/2 trial of indoximod in combination with a dendritic cell cancer vaccine (AD.p53DC) was conducted in 32 patients with metasta
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
2. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
3. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
4. NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
5. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
6. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
7. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
8. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
9. Lota S. Zoth joins NewLinks Board of Directors; heads Audit Committee
10. Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
11. Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 ... company") announced today a protocol amendment to allow for expanded ... the U.S. Food and Drug Administration (FDA) and that a ... opened at three clinical trial sites in the ... proceeds of US$2.9 million have been raised through warrant exercise ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. 19, 2014 ... North Premier, Stockholm : "IMNP"), a biotechnology ... application to list its common stock on the NASDAQ Capital ... unit of the NASDAQ OMX Group. IMMUNE,s common stock is ... the opening of trading on August 21, 2014 under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Dec. 27, 2011 Neuralstem, Inc. (NYSE Amex: ... Food and Drug Administration to advance to Phase Ib in ... NSI-189, for the treatment of major depressive disorder ... the drug in depressed patients. NSI-189 is a proprietary new ...
... Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... Medicines ("TCM") in China, today announced that the ... 66th PHARMCHINA fair ("the Fair") recently held in ...
Cached Medicine Technology:Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 2Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 3Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 4China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3
(Date:8/20/2014)... they often have difficulty falling asleep and staying asleep, ... In individuals with Alzheimer,s disease, this common and troubling ... leading to nighttime confusion and wandering. , Now, a ... Center (BIDMC) and the University of Toronto/Sunnybrook Health Sciences ... age. Reported online today in the journal Brain ...
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... will honor the 2014 Emmy Award Nominees and Presenters at ... place on August 22nd and 23rd in Beverly Hills from ... enjoy gifts, refreshments and music by DJ Morgan Hildebrand. , ... charity fundraising and will feature several charities at the lounge. ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 Over 31 ... Global Bureau of Disease, low back pain is the single ... most common reasons for missed work. Americans spend at least ... pain. , Most cases of back pain are not due ... (non-organic) origin. , For example, Pete, a busy accountant, had ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 As moms and ... for themselves to return to the normal routine of dropping ... in tow, Kristen Yarker, MSc, RD encourages them to ... their kids’ snack time. , Yarker explains, “Kids have ... nutrients. Instead of giving them junk food handouts, use snack ...
Breaking Medicine News(10 mins):Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... of stroke victims suffer vision difficulties due to cortical ... holds immense promise for patients suffering partial impairment of ... medical instrument has been devised that is capable of ... This could indeed be the light at the end ...
... gene expression in the mouse brain is considered a scientific ... or 57.7 million people//. , ,The Allen Institute ... The Allen Institute was started in 2003 and the Atlas ... given by Microsoft co-founder Paul G. Allen funded both. ...
... Sufferers,Television personality Angela Rippon is fronting a new DVD ... Chronic Obstructive Pulmonary Disease (COPD). The DVD called Move ... ,COPD includes a range of lung diseases like chronic ... make a difference to the lives of people living ...
... HIV/AIDS is a major hindrance in controlling the fast-spreading disease ... discrimination are indeed problem areas in tackling HIV/AIDS in India," ... for HIV/AIDS in Asia and the Pacific. ,"There ... lots needs to be done to make it (the disease) ...
... for the cartoon man, Popeye, who simply preens at the ... spinach and an icon that little kids swear by, what ... who still boasts of a perfect vision without the help ... with a novel eye device are trying to understand the ...
... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
Cached Medicine News:Health News:Allen Brain Atlas – a 3-D gene map of brai 2Health News:Remove Stigma to Defeat HIV/AIDS in India, says UN Envoy 2Health News:Go Green with Popeye: Learn why his eyes pop out for spinach! 2
... Implant System provides todays surgeon with ... head replacement. Modular stem and ... while minimizing ligamentous and soft tissue ... guide assists in both the radial ...
... modular radial head system employs the advantages ... to create the next generation of modular ... part, modular design, the implant system offers ... the patients anatomy. In addition, the capability ...
All Padgett bipolar forceps are foot activated. The standard-type connectors fit generators utilizing the standard receivers for small "banana" inserts. All Padgett bipolar foot activated forceps an...
For connection to the bipolar output of electrosurgical generators....
Medicine Products: